 |
NCCN Non-Small Cell Lung Cancer Guidelines Update CME/CE
David S. Ettinger, MD; Mark G. Kris, MD Author Information and Disclosures
Release Date: May 16, 2008; Valid for credit through May 16, 2009
|
Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 0.7 ANCC contact hours
|
|
A presentation from the NCCN 13th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care™ held in Hollywood, Florida. This activity is designed to be completed within approximately 40 minutes.
To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the educational content; (3) take the post-test and complete the evaluation; (4) view/print certificate View details.
Contents of This CME/CE Activity
Legal Disclaimer
The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
Copyright © 2008 National Comprehensive Cancer Network
|
|
|
Learning ObjectivesFollowing this activity, participants should be able to:
- Discuss updates to NCCN guidelines for non-small cell lung cancer
- Explain how these updates will impact the management of non-small cell lung cancer
Author Disclosures
David S. Ettinger, MD
Alex Grass Professor of Oncology and Professor of Medicine, Otolaryngology-Head and Neck Surgery, Obstetrics and Gynecology, and Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland
Disclosure: Dr. Ettinger has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of any products or devices to be discussed in this activity or who may financially support the activity. He has served as a consultant, scientific advisor, and product/speakers' bureau member for AstraZeneca Pharmaceuticals Corporation; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; Merck & Co., Inc.; MGI PHARMA, Inc.; Pfizer Inc.; and sanofi-aventis U.S. He has also served as a scientific advisor for Genentech, Inc. and has received grant/research support from Bayer HealthCare Pharmaceuticals; Genentech, Inc.; and Pharmion Corporation.
Dr. Ettinger has indicated that his presentation will not include discussion of investigational or unlabeled uses of commercial products.
Mark G. Kris, MD
Chief of Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center; Associate Chairman Clinical Trials, Department of Medicine, Memorial Sloan-Kettering Cancer Center; Professor of Medicine, Weill Medical College of Cornell University, New York, New York
Disclosure: Dr. Kris has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of products or devices to be discussed in this activity or who may financially support the activity. He has served as a consultant for Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, and Pfizer Inc. He has also received grant/research support from sanofi-aventis U.S.
Dr. Kris has indicated that his presentation will include discussion of investigational or unlabeled uses of commercial products.
|
 |
The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing education for physicians.
NCCN designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)". Physicians should only claim credit commensurate with the extent of their participation in the activity.
|
This activity is approved for 0.7 contact hours. National Comprehensive Cancer Network is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product.
Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.
More Activities from NCCN
|
|
